Novo Nordisk / Aradigm link on insulin device:
This article was originally published in Clinica
Executive Summary
Novo Nordisk and Aradigm plan the joint development of a pulmonary insulin delivery system, based on Aradigm's AerX drug delivery system. The deal includes other glucose-regulatory compounds as well as two other, unnamed and unrelated therapeutics. Novo gains worldwide rights to any of the resulting products and Aradigm gains $9 million in upfront payments and equity investment, with a total of $50 million in possible milestone payments thereafter. Aradigm is based in Hayward, California.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.